{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:44:28Z","timestamp":1787021068805,"version":"build-2736575974"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j intensive care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Granulomonocytapheresis (GMA) has long been used to treat refractory chronic inflammatory diseases. Recently, an exploratory clinical study showed that GMA was effective for sepsis, and its use has been approved in Japan. The purpose of this review is to spread the knowledge about GMA in chronic and acute inflammation. GMA is a selective extracorporeal therapy designed to remove activated granulocytes and monocytes, key drivers of inflammation in various immune-mediated diseases. Initially developed for ulcerative colitis, GMA has since demonstrated immunomodulatory effects in conditions such as Crohn\u2019s disease, rheumatoid arthritis, and dermatologic disorders, by depleting activated myeloid cells and altering cytokine profiles, reducing tumor necrosis factor (TNF)-\u03b1, interleukin (IL)-6, and increasing IL-10. GMA aims to restore immune homeostasis without the systemic immunosuppression associated with pharmacologic agents. Recently, its application has expanded to critical care settings. In sepsis and cytokine storm syndromes, where overwhelming innate immune activation leads to organ dysfunction, GMA may offer therapeutic benefit. Preclinical models and pilot studies in septic patients suggest that GMA can reduce inflammatory mediators, improve hemodynamics, and support organ recovery. Reflecting this potential, GMA was approved for insurance reimbursement in Japan in August 2025 as adjunctive therapy for sepsis with systemic inflammation. Although GMA is a promising therapy for specific patients, there is limited supporting data, and its effect should be proven in future trials.<\/jats:p>","DOI":"10.1186\/s40560-025-00825-8","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:20:14Z","timestamp":1759490414000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Granulomonocytapheresis for chronic inflammatory diseases and sepsis"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0255-4088","authenticated-orcid":false,"given":"Toshiaki","family":"Iba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideshi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Mineshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4859-4747","authenticated-orcid":false,"given":"Ricard","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"issue":"4","key":"825_CR1","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s00535-019-01651-0","volume":"55","author":"M Naganuma","year":"2020","unstructured":"Naganuma M, Yokoyama Y, Motoya S, Watanabe K, Sawada K, Hirai F, et al. Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial. J Gastroenterol. 2020;55(4):390\u2013400.","journal-title":"J Gastroenterol"},{"issue":"5","key":"825_CR2","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s10620-009-0845-x","volume":"55","author":"B Habermalz","year":"2010","unstructured":"Habermalz B, Sauerland S. Clinical effectiveness of selective granulocyte, monocyte adsorptive apheresis with the Adacolumn device in ulcerative colitis. Dig Dis Sci. 2010;55(5):1421\u20138.","journal-title":"Dig Dis Sci"},{"issue":"10","key":"825_CR3","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1097\/MCG.0b013e3180479435","volume":"41","author":"MT Abreu","year":"2007","unstructured":"Abreu MT, Plevy S, Sands BE, Weinstein R. Selective leukocyte apheresis for the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2007;41(10):874\u201388.","journal-title":"J Clin Gastroenterol"},{"issue":"17","key":"825_CR4","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.2169\/internalmedicine.1728-23","volume":"62","author":"S Kaneko","year":"2023","unstructured":"Kaneko S, Zen T, Banjoya S, Nuki T, Hoshimoto A, Harano M, et al. Successful use of granulocyte and monocyte adsorptive apheresis in a patient with post-COVID-19 multisystem inflammatory syndrome in adults. Intern Med. 2023;62(17):2565\u20139.","journal-title":"Intern Med"},{"issue":"5","key":"825_CR5","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/aor.14943","volume":"49","author":"O Nishida","year":"2025","unstructured":"Nishida O, Nakamura T, Nakada T, Takahashi G, Masuda Y, Tsubouchi H, et al. Granulocyte and monocyte adsorption therapy in patients with sepsis: a feasibility study. Artif Organs. 2025;49(5):852\u201363.","journal-title":"Artif Organs"},{"issue":"1","key":"825_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s40635-017-0129-2","volume":"5","author":"S Ma","year":"2017","unstructured":"Ma S, Xu Q, Deng B, Zheng Y, Tian H, Wang L, et al. Granulocyte and monocyte adsorptive apheresis ameliorates sepsis in rats. Intensive Care Med Exp. 2017;5(1):18.","journal-title":"Intensive Care Med Exp"},{"key":"825_CR7","unstructured":"https:\/\/www.jimro.co.jp\/news\/news_release_20250801.pdf"},{"issue":"1","key":"825_CR8","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1186\/s12967-022-03752-6","volume":"20","author":"L Zhou","year":"2022","unstructured":"Zhou L, Zhang D, Kong L, Xu X, Gong D. Clinical improvement of sepsis by extracorporeal centrifugal leukocyte apheresis in a porcine model. J Transl Med. 2022;20(1):538.","journal-title":"J Transl Med"},{"issue":"3","key":"825_CR9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.dld.2013.10.011","volume":"46","author":"T Yoshino","year":"2014","unstructured":"Yoshino T, Nakase H, Minami N, Yamada S, Matsuura M, Yazumi S, et al. Efficacy and safety of granulocyte and monocyte adsorption apheresis for ulcerative colitis: a meta-analysis. Dig Liver Dis. 2014;46(3):219\u201326.","journal-title":"Dig Liver Dis"},{"issue":"4","key":"825_CR10","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1080\/00365521.2018.1447598","volume":"53","author":"A Dignass","year":"2018","unstructured":"Dignass A, Akbar A, Baumgart DC, Bommelaer G, Bouguen G, Cadiot G, et al. Granulocyte\/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis. Scand J Gastroenterol. 2018;53(4):442\u20138.","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"825_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1365-2249.2010.04279.x","volume":"163","author":"H Hanai","year":"2011","unstructured":"Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, et al. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol. 2011;163(1):50\u20138.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"825_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1046\/j.1526-0968.2003.00012.x","volume":"7","author":"AR Saniabadi","year":"2003","unstructured":"Saniabadi AR, Hanai H, Takeuchi K, Umemura K, Nakashima M, Adachi T, et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial. 2003;7(1):48\u201359.","journal-title":"Ther Apher Dial"},{"issue":"2","key":"825_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.transci.2007.08.003","volume":"37","author":"AR Saniabadi","year":"2007","unstructured":"Saniabadi AR, Hanai H, Fukunaga K, Sawada K, Shima C, Bjarnason I, et al. Therapeutic leukocytapheresis for inflammatory bowel disease. Transfus Apher Sci. 2007;37(2):191\u2013200.","journal-title":"Transfus Apher Sci"},{"issue":"4","key":"825_CR14","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1159\/000341801","volume":"39","author":"CG Leitner","year":"2012","unstructured":"Leitner CG, Worel N, Vogelsang H. Selective granulocyte and monocyte apheresis as a non-pharmacological option for patients with inflammatory bowel disease. Transfus Med Hemother. 2012;39(4):246\u201352.","journal-title":"Transfus Med Hemother"},{"issue":"8","key":"825_CR15","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/00054725-200608000-00008","volume":"12","author":"T Yamamoto","year":"2006","unstructured":"Yamamoto T, Saniabadi AR, Umegae S, Matsumoto K. Impact of selective leukocytapheresis on mucosal inflammation and ulcerative colitis: cytokine profiles and endoscopic findings. Inflamm Bowel Dis. 2006;12(8):719\u201326.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"825_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/jca.20046","volume":"20","author":"AR Saniabadi","year":"2005","unstructured":"Saniabadi AR, Hanai H, Suzuki Y, Ohmori T, Sawada K, Yoshimura N, et al. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J Clin Apher. 2005;20(3):171\u201384.","journal-title":"J Clin Apher"},{"issue":"9","key":"825_CR17","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/j.cell.2024.03.037","volume":"187","author":"H Chi","year":"2024","unstructured":"Chi H, Pepper M, Thomas PG. Principles and therapeutic applications of adaptive immunity. Cell. 2024;187(9):2052\u201378.","journal-title":"Cell"},{"issue":"1","key":"825_CR18","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.cyto.2013.01.019","volume":"62","author":"Y Toya","year":"2013","unstructured":"Toya Y, Chiba T, Mizutani T, Sato K, Kasugai S, Matsuda N, et al. The effect of granulocyte and monocyte adsorptive apheresis on serum cytokine levels in patients with ulcerative colitis. Cytokine. 2013;62(1):146\u201350.","journal-title":"Cytokine"},{"key":"825_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2020.155410","volume":"139","author":"N Kashiwagi","year":"2021","unstructured":"Kashiwagi N, Saito F, Maegawa H, Kaneda K. Granulocyte and monocyte adsorptive apheresis induces apoptosis of neutrophils and release of a novel chemoattractant for desensitization of interleukin-8 response - In vitro and in vivo results. Cytokine. 2021;139:155410.","journal-title":"Cytokine"},{"issue":"4","key":"825_CR20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1358\/mf.2007.29.4.1075361","volume":"29","author":"N Tomiyasu","year":"2007","unstructured":"Tomiyasu N, Mitsuyama K, Suzuki A, Masuda J, Yamasaki H, Kuwaki K, et al. Development of granulocyte and monocyte adsorptive apheresis in the rat dextran sodium sulfate-induced colitis model. Methods Find Exp Clin Pharmacol. 2007;29(4):265\u20138.","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"Suppl 3","key":"825_CR21","doi-asserted-by":"publisher","first-page":"S166","DOI":"10.1007\/s000110050311","volume":"47","author":"M Kyogoku","year":"1998","unstructured":"Kyogoku M, Kasukawa R. Clinical and basic studies on the G-1 column, a new extracorporeal therapeutic device effective in controlling rheumatoid arthritis. Inflamm Res. 1998;47(Suppl 3):S166\u201376.","journal-title":"Inflamm Res"},{"issue":"4","key":"825_CR22","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3109\/s10165-005-0402-1","volume":"15","author":"S Nakazato","year":"2005","unstructured":"Nakazato S, Takase H, Yanagihara Y, Issekutz TB, Issekutz AC, Takai M, et al. Effect of G-1 column (Adacolumn) therapy in rats with adjuvant arthritis on the migration and immunoreactivity of peripheral and splenic leukocytes. Mod Rheumatol. 2005;15(4):249\u201357.","journal-title":"Mod Rheumatol"},{"issue":"5","key":"825_CR23","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/j.1744-9987.2012.01110.x","volume":"16","author":"S Nishise","year":"2012","unstructured":"Nishise S, Sato T, Sasaki Y, Nagino K, Iwano D, Yaoita T, et al. Production of interleukin-10 by combining a granulocyte and monocyte adsorption carrier with ulinastatin. Ther Apher Dial. 2012;16(5):449\u201355.","journal-title":"Ther Apher Dial"},{"issue":"12","key":"825_CR24","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1007\/s00535-004-1465-z","volume":"39","author":"Y Fukuda","year":"2004","unstructured":"Fukuda Y, Matsui T, Suzuki Y, Kanke K, Matsumoto T, Takazoe M, et al. Adsorptive granulocyte and monocyte apheresis for refractory Crohn\u2019s disease: an open multicenter prospective study. J Gastroenterol. 2004;39(12):1158\u201364.","journal-title":"J Gastroenterol"},{"issue":"7","key":"825_CR25","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41424-018-0037-0.Erratum.In:ClinTranslGastroenterol.2018;9(10):192","volume":"9","author":"T Yamamoto","year":"2018","unstructured":"Yamamoto T, Iida T, Ikeya K, Kato M, Matsuura A, Tamura S, et al. A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis. Clin Transl Gastroenterol. 2018;9(7):170. https:\/\/doi.org\/10.1038\/s41424-018-0037-0.Erratum.In:ClinTranslGastroenterol.2018;9(10):192.","journal-title":"Clin Transl Gastroenterol"},{"issue":"12","key":"825_CR26","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1038\/ajg.2009.453","volume":"104","author":"A Sakuraba","year":"2009","unstructured":"Sakuraba A, Motoya S, Watanabe K, Nishishita M, Kanke K, Matsui T, et al. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol. 2009;104(12):2990\u20135.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"825_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.5009\/gnl.2012.6.4.427","volume":"6","author":"K Fukunaga","year":"2012","unstructured":"Fukunaga K, Yokoyama Y, Kamokozuru K, Nagase K, Nakamura S, Miwa H, et al. Adsorptive granulocyte\/monocyte apheresis for the maintenance of remission in patients with ulcerative colitis: a prospective randomized, double blind, sham-controlled clinical trial. Gut Liver. 2012;6(4):427\u201333.","journal-title":"Gut Liver"},{"issue":"1","key":"825_CR28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000080079","volume":"70","author":"H Hanai","year":"2004","unstructured":"Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, et al. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion. 2004;70(1):36\u201344.","journal-title":"Digestion"},{"issue":"2","key":"825_CR29","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/rheumatology\/39.2.165","volume":"39","author":"Y Ueki","year":"2000","unstructured":"Ueki Y, Yamasaki S, Kanamoto Y, Kawazu T, Yano M, Matsumoto K, et al. Evaluation of filtration leucocytapheresis for use in the treatment of patients with rheumatoid arthritis. Rheumatology (Oxford). 2000;39(2):165\u201371.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"825_CR30","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1136\/gutjnl-2011-300995","volume":"62","author":"BE Sands","year":"2013","unstructured":"Sands BE, Katz S, Wolf DC, Feagan BG, Wang T, Gustofson LM, et al. A randomised, double-blind, sham-controlled study of granulocyte\/monocyte apheresis for moderate to severe Crohn\u2019s disease. Gut. 2013;62(9):1288\u201394.","journal-title":"Gut"},{"key":"825_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-015-0390-3","volume":"15","author":"N Yoshimura","year":"2015","unstructured":"Yoshimura N, Yokoyama Y, Matsuoka K, Takahashi H, Iwakiri R, Yamamoto T, et al. An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn\u2019s disease. BMC Gastroenterol. 2015;15:163.","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"825_CR32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/jca.1016","volume":"16","author":"T Hidaka","year":"2001","unstructured":"Hidaka T, Suzuki K, Kawakami M, Okada M, Kataharada K, Shinohara T, et al. Dynamic changes in cytokine levels in serum and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis. J Clin Apher. 2001;16(2):74\u201381.","journal-title":"J Clin Apher"},{"issue":"5","key":"825_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-042374","volume":"11","author":"S Kiss","year":"2021","unstructured":"Kiss S, N\u00e9meth D, Hegyi P, F\u00f6ldi M, Szak\u00e1cs Z, Er\u0151ss B, et al. Granulocyte and monocyte apheresis as an adjunctive therapy to induce and maintain clinical remission in ulcerative colitis: a systematic review and meta-analysis. BMJ Open. 2021;11(5):e042374.","journal-title":"BMJ Open"},{"key":"825_CR34","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1016\/j.ejim.2016.08.028","volume":"36","author":"Z Liu","year":"2016","unstructured":"Liu Z, Jiang X, Sun C. The efficacy and safety of selective granulocyte and monocyte apheresis for inflammatory bowel disease: A meta-analysis. Eur J Intern Med. 2016;36:e26\u20137.","journal-title":"Eur J Intern Med"},{"issue":"2","key":"825_CR35","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1053\/j.gastro.2008.04.023","volume":"135","author":"BE Sands","year":"2008","unstructured":"Sands BE, Sandborn WJ, Feagan B, L\u00f6fberg R, Hibi T, Wang T, et al. A randomized, double-blind, sham-controlled study of granulocyte\/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008;135(2):400\u20139.","journal-title":"Gastroenterology"},{"key":"825_CR36","doi-asserted-by":"publisher","first-page":"9728324","DOI":"10.1155\/2017\/9728324","volume":"2017","author":"G Imperiali","year":"2017","unstructured":"Imperiali G, Amato A, Terpin MM, Beverina I, Bortoli A, Devani M, et al. Granulocyte-monocyte apheresis in steroid-dependent, azathioprine-intolerant\/resistant moderate ulcerative colitis: a prospective multicenter study. Gastroenterol Res Pract. 2017;2017:9728324.","journal-title":"Gastroenterol Res Pract"},{"issue":"3","key":"825_CR37","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/1744-9987.14103","volume":"28","author":"N Ueno","year":"2024","unstructured":"Ueno N, Saito S, Sato M, Sugiyama Y, Kobayashi Y, Murakami Y, et al. The clinical efficacy and safety of granulocyte and monocyte adsorptive apheresis in patients with Crohn\u2019s disease: a multicenter retrospective pilot study. Ther Apher Dial. 2024;28(3):442\u201352.","journal-title":"Ther Apher Dial"},{"issue":"9","key":"825_CR38","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1093\/rheumatology\/keh701","volume":"44","author":"R Sanmart\u00ed","year":"2005","unstructured":"Sanmart\u00ed R, Marsal S, Valverde J, Casado E, Lafuente R, Kashiwagi N, et al. Adsorptive granulocyte\/monocyte apheresis for the treatment of refractory rheumatoid arthritis: an open pilot multicentre trial. Rheumatology. 2005;44(9):1140\u20134.","journal-title":"Rheumatology"},{"issue":"4","key":"825_CR39","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.autrev.2008.09.001","volume":"8","author":"E Cuadrado","year":"2009","unstructured":"Cuadrado E. Granulocyte\/monocyte apheresis as immunotherapic tool: cellular adsorption and immune modulation. Autoimmun Rev. 2009;8(4):292\u20136.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"825_CR40","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1023\/A:1016523914161","volume":"26","author":"N Kashiwagi","year":"2002","unstructured":"Kashiwagi N, Nakano M, Saniabadi AR, Adachi M, Yoshikawa T. Anti-inflammatory effect of granulocyte and monocyte adsorption apheresis in a rabbit model of immune arthritis. Inflammation. 2002;26(4):199\u2013205.","journal-title":"Inflammation"},{"issue":"4","key":"825_CR41","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/1744-9987.14118","volume":"28","author":"M Seishima","year":"2024","unstructured":"Seishima M, Hachiken H, Furukawa T, Yamamoto J. Successful treatment with granulocyte and monocyte adsorption apheresis for plaque-type skin lesions in patients with psoriatic arthritis. Ther Apher Dial. 2024;28(4):511\u20135.","journal-title":"Ther Apher Dial"},{"issue":"2","key":"825_CR42","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S0190-9622(03)02474-5","volume":"50","author":"T Kanekura","year":"2004","unstructured":"Kanekura T, Kawabata H, Maruyama I, Kanzaki T. Treatment of psoriatic arthritis with granulocyte and monocyte adsorption apheresis. J Am Acad Dermatol. 2004;50(2):242\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"825_CR43","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/1744-9987.12113","volume":"17","author":"M Sakanoue","year":"2013","unstructured":"Sakanoue M, Takeda K, Kawai K, Kanekura T. Granulocyte and monocyte adsorption apheresis for refractory skin diseases due to activated neutrophils, psoriasis, and associated arthropathy. Ther Apher Dial. 2013;17(5):477\u201383.","journal-title":"Ther Apher Dial"},{"issue":"2","key":"825_CR44","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/1744-9987.13720","volume":"26","author":"Y Higashi","year":"2022","unstructured":"Higashi Y, Ibusuki A, Baba N, Hatanaka M, Tada KI, Kanekura T. Granulocyte and monocyte adsorptive apheresis for pyoderma gangrenosum. Ther Apher Dial. 2022;26(2):450\u20135.","journal-title":"Ther Apher Dial"},{"issue":"3","key":"825_CR45","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1744-9987.2007.00424.x","volume":"11","author":"M Seishima","year":"2007","unstructured":"Seishima M, Mizutani Y, Shibuya Y, Nagasawa C, Aoki T. Efficacy of granulocyte and monocyte adsorption apheresis for three cases of refractory pyoderma gangrenosum. Ther Apher Dial. 2007;11(3):177\u201382.","journal-title":"Ther Apher Dial"},{"issue":"10","key":"825_CR46","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1007\/s00134-024-07586-2","volume":"50","author":"M Girardis","year":"2024","unstructured":"Girardis M, David S, Ferrer R, Helms J, Juffermans NP, Martin-Loeches I, et al. Understanding, assessing and treating immune, endothelial and haemostasis dysfunctions in bacterial sepsis. Intensive Care Med. 2024;50(10):1580\u201392.","journal-title":"Intensive Care Med"},{"issue":"5","key":"825_CR47","doi-asserted-by":"publisher","first-page":"R613","DOI":"10.1152\/ajpregu.00003.2023","volume":"324","author":"J Arora","year":"2023","unstructured":"Arora J, Mendelson AA, Fox-Robichaud A. Sepsis: network pathophysiology and implications for early diagnosis. Am J Physiol Regul Integr Comp Physiol. 2023;324(5):R613\u201324.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"825_CR48","doi-asserted-by":"publisher","first-page":"1352946","DOI":"10.3389\/fimmu.2024.1352946","volume":"15","author":"M Luo","year":"2024","unstructured":"Luo M, Zhao F, Cheng H, Su M, Wang Y. Macrophage polarization: an important role in inflammatory diseases. Front Immunol. 2024;15:1352946.","journal-title":"Front Immunol"},{"issue":"4","key":"825_CR49","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/1744-9987.12338","volume":"19","author":"Y Hara","year":"2015","unstructured":"Hara Y, Shimomura Y, Nakamura T, Kuriyama N, Yamashita C, Kato Y, et al. Novel blood purification system for regulating excessive immune reactions in severe sepsis and septic shock: an ex vivo pilot study. Ther Apher Dial. 2015;19(4):308\u201315.","journal-title":"Ther Apher Dial"},{"key":"825_CR50","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s41100-024-00565-9","volume":"10","author":"T Nakamura","year":"2024","unstructured":"Nakamura T, Moriyama K, Sakai T, Sakai T, Toki Y, Nishida O. Changes in cytokine concentrations during passage through a granulocyte and monocyte adsorption column in a porcine lipopolysaccharide-induced inflammation model. Ren Replace Ther. 2024;10:51.","journal-title":"Ren Replace Ther"},{"issue":"1","key":"825_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/ams2.70003","volume":"11","author":"R Hisamune","year":"2024","unstructured":"Hisamune R, Yamakawa K, Kayano K, Ushio N, Wada T, Taniguchi K, et al. Phenotypic changes in immune cells induced by granulocyte and monocyte adsorptive apheresis in patients with severe COVID-19: an ex vivo study. Acute Med Surg. 2024;11(1):e70003.","journal-title":"Acute Med Surg"},{"key":"825_CR52","doi-asserted-by":"publisher","DOI":"10.1055\/a-2657-6380","author":"T Iba","year":"2025","unstructured":"Iba T, Helms J, Maier CL, Ferrer R, Levy JH. Evolution of Clinical Trials in Anticoagulation for Sepsis: Bridging Past to Future. Semin Thromb Hemost. 2025. https:\/\/doi.org\/10.1055\/a-2657-6380.","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"825_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192949","volume":"13","author":"V Balbas-Martinez","year":"2018","unstructured":"Balbas-Martinez V, Ruiz-Cerd\u00e1 L, Irurzun-Arana I, Gonz\u00e1lez-Garc\u00eda I, Vermeulen A, G\u00f3mez-Mantilla JD, et al. A systems pharmacology model for inflammatory bowel disease. PLoS ONE. 2018;13(3):e0192949.","journal-title":"PLoS ONE"},{"issue":"3","key":"825_CR54","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41591-020-0752-4","volume":"26","author":"M Reyes","year":"2020","unstructured":"Reyes M, Filbin MR, Bhattacharyya RP, Billman K, Eisenhaure T, Hung DT, et al. An immune-cell signature of bacterial sepsis. Nat Med. 2020;26(3):333\u201340.","journal-title":"Nat Med"},{"issue":"7","key":"825_CR55","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.dld.2007.03.007","volume":"39","author":"J Pan\u00e9s","year":"2007","unstructured":"Pan\u00e9s J, Guilera M, Ginard D, Hinojosa J, Gonz\u00e1lez-Carro P, Gonz\u00e1lez-Lara V, et al. Treatment cost of ulcerative colitis is apheresis with Adacolumn cost-effective? Dig Liver Dis. 2007;39(7):617\u201325.","journal-title":"Dig Liver Dis"},{"key":"825_CR56","unstructured":"https:\/\/spectraldx.com\/spectral-medical-and-vantive-announce-topline-results-from-spectrals-tigris-trial-evaluating-pmx-hemoadsorption-therapy-for-endotoxic-septic-shock\/"},{"issue":"1","key":"825_CR57","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s40001-023-01184-6","volume":"28","author":"Y Nakamura","year":"2023","unstructured":"Nakamura Y, Hatomoto H, Yamasaki S, Yamauchi K, Kiyomi F, Hoshino K, et al. Comparison of the cytokine adsorption ability in continuous renal replacement therapy using polyethyleneimine-coated polyacrylonitrile (AN69ST) or polymethylmethacrylate (PMMA) hemofilters: a pilot single-center open-label randomized control trial. Eur J Med Res. 2023;28(1):208.","journal-title":"Eur J Med Res"}],"container-title":["Journal of Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40560-025-00825-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40560-025-00825-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40560-025-00825-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:04:01Z","timestamp":1759493041000},"score":1,"resource":{"primary":{"URL":"https:\/\/jintensivecare.biomedcentral.com\/articles\/10.1186\/s40560-025-00825-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["825"],"URL":"https:\/\/doi.org\/10.1186\/s40560-025-00825-8","relation":{},"ISSN":["2052-0492"],"issn-type":[{"value":"2052-0492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"16 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}